Bandingkan Harga & Kinerja Mora Telematika Indonesia Tbk. (MORA) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Mora Telematika Indonesia Tbk. dan Organon Pharma Indonesia Tbk.: Mora Telematika Indonesia Tbk. diperdagangkan di Rp5.175 (kapitalisasi pasar 254,4 T, volume 24 jam 166 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Mora Telematika Indonesia Tbk. jauh lebih besar — sekitar 2436,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| MORA | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 254,4 T | 104,4 M |
Volume | 166 rb | — |
Lot | 1,66 rb | — |
Perputaran | 863,82 jt | — |
Harga Rata-rata | 5.203,75 | — |
Nilai Transaksi | 863,82 jt | — |
Harga Ekuilibrium Indikatif | 5.175 | — |
Volume Ekuilibrium Indikatif | 45 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Mora Telematika Indonesia Tbk.
PT Mora Telematika Indonesia Tbk (the Company) was established based on the Notarial Deed No. 30 dated August 8, 2000 of Daniel Parganda Marpaung, S.H., a public notary in Jakarta. The Company started its commercial operations in 2001. PT Candrakarya Multikreasi is the parent company. Ir. Galumbang Menak and Farida Bau are the ultimate shareholders of the Company and its subsidiaries (herein after referred to as the Group). The Group is incorporated in Indonesia and conduct its operations in Indonesia and Singapore.
Selengkapnya di halaman MORA →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
